Tokyo Tape
Sign in
← Chiome Bioscience

Quarterly report · Q3

4583.TEDINET S100S992
Period2023-01-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥524m2023-01-01 → 2023-09-30StandaloneNet sales
Revenue¥631m2022-01-01 → 2022-12-31StandaloneNet sales (5-year summary)
Revenue¥434m2022-01-01 → 2022-09-30StandaloneNet sales
Operating income−¥905m2023-01-01 → 2023-09-30StandaloneOperating income
Operating income−¥1.0bn2022-01-01 → 2022-09-30StandaloneOperating income
Ordinary income−¥916m2023-01-01 → 2023-09-30StandaloneOrdinary income
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.0bn2022-01-01 → 2022-09-30StandaloneOrdinary income
Profit before tax−¥915m2023-01-01 → 2023-09-30StandaloneIncome before income taxes
Profit before tax−¥1.0bn2022-01-01 → 2022-09-30StandaloneIncome before income taxes
Net income−¥918m2023-01-01 → 2023-09-30StandaloneProfit loss
Net income−¥1.2bn2022-01-01 → 2022-12-31StandaloneNet income loss (5-year summary)
Net income−¥1.0bn2022-01-01 → 2022-09-30StandaloneProfit loss
Total assets¥1.8bnat 2023-09-30StandaloneAssets
Total assets¥2.2bnat 2022-12-31StandaloneAssets
Total assets¥2.1bnat 2022-09-30StandaloneTotal assets (5-year summary)
Total liabilities¥542mat 2023-09-30StandaloneLiabilities
Total liabilities¥425mat 2022-12-31StandaloneLiabilities
Net assets / equity¥1.2bnat 2023-09-30StandaloneNet assets
Net assets / equity¥1.8bnat 2022-12-31StandaloneNet assets
Net assets / equity¥1.7bnat 2022-09-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.3bnat 2023-09-30StandaloneCash and deposits
Cash and deposits¥1.7bnat 2022-12-31StandaloneCash and deposits
EPS (basic)¥-18.822023-01-01 → 2023-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-5.152023-07-01 → 2023-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-28.262022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-23.872022-01-01 → 2022-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-5.82022-07-01 → 2022-09-30dStandaloneBasic earnings loss per share (5-year summary)
Equity ratio67.8%at 2023-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio80.2%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio78.4%at 2022-09-30StandaloneEquity to asset ratio (5-year summary)
Shares issued50,571,400at 2023-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued48,423,500at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued45,979,100at 2022-09-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-09-30−¥409m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2023-01-01 → 2023-09-30−¥803m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue2023-01-01 → 2023-09-30¥524m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue external2023-01-01 → 2023-09-30¥524m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentsegment profit2023-01-01 → 2023-09-30¥307m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-09-30¥524m
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-09-30¥524m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-09-30−¥496m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥358m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2022-01-01 → 2022-09-30−¥916m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue2022-01-01 → 2022-09-30¥434m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue external2022-01-01 → 2022-09-30¥434m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentsegment profit2022-01-01 → 2022-09-30¥235m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-09-30¥434m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-09-30¥434m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-09-30−¥681m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 329
ItemContextValueUnit
Gross profitCurrentYTDDuration_NonConsolidatedMember307091000JPY
Research and development expenses sgaPrior1YTDDuration_NonConsolidatedMember916417000JPY
Research and development expenses sgaCurrentYTDDuration_NonConsolidatedMember803247000JPY
Other sgaPrior1YTDDuration_NonConsolidatedMember357902000JPY
Other sgaCurrentYTDDuration_NonConsolidatedMember409157000JPY
Selling general and administrative expensesPrior1YTDDuration_NonConsolidatedMember1274320000JPY
Selling general and administrative expensesCurrentYTDDuration_NonConsolidatedMember1212405000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember-1039329000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember-905313000JPY
Interest income noiPrior1YTDDuration_NonConsolidatedMember19000JPY
Interest income noiCurrentYTDDuration_NonConsolidatedMember17000JPY
Foreign exchange gains noiPrior1YTDDuration_NonConsolidatedMember－JPY
Foreign exchange gains noiCurrentYTDDuration_NonConsolidatedMember251000JPY
Subsidy income noiPrior1YTDDuration_NonConsolidatedMember16000000JPY
Subsidy income noiCurrentYTDDuration_NonConsolidatedMember－JPY
Other noiPrior1YTDDuration_NonConsolidatedMember210000JPY
Other noiCurrentYTDDuration_NonConsolidatedMember432000JPY
Non operating incomePrior1YTDDuration_NonConsolidatedMember16230000JPY
Non operating incomeCurrentYTDDuration_NonConsolidatedMember702000JPY
Interest expenses noePrior1YTDDuration_NonConsolidatedMember980000JPY
Interest expenses noeCurrentYTDDuration_NonConsolidatedMember1481000JPY
Stock issuance cost noePrior1YTDDuration_NonConsolidatedMember2393000JPY
Stock issuance cost noeCurrentYTDDuration_NonConsolidatedMember1785000JPY
Share acquisition rights issuance costs noePrior1YTDDuration_NonConsolidatedMember－JPY
Share acquisition rights issuance costs noeCurrentYTDDuration_NonConsolidatedMember7705000JPY
Foreign exchange losses noePrior1YTDDuration_NonConsolidatedMember3020000JPY
Foreign exchange losses noeCurrentYTDDuration_NonConsolidatedMember－JPY
Other noePrior1YTDDuration_NonConsolidatedMember286000JPY
Other noeCurrentYTDDuration_NonConsolidatedMember655000JPY
Non operating expensesPrior1YTDDuration_NonConsolidatedMember6680000JPY
Non operating expensesCurrentYTDDuration_NonConsolidatedMember11627000JPY
Ordinary incomePrior1YTDDuration_NonConsolidatedMember-1029779000JPY
Ordinary incomeCurrentYTDDuration_NonConsolidatedMember-916239000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration_NonConsolidatedMember－JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration_NonConsolidatedMember119000JPY
Gain on reversal of subscription rights to shares eiPrior1YTDDuration_NonConsolidatedMember5977000JPY
Gain on reversal of subscription rights to shares eiCurrentYTDDuration_NonConsolidatedMember1426000JPY
Extraordinary incomePrior1YTDDuration_NonConsolidatedMember5977000JPY
Extraordinary incomeCurrentYTDDuration_NonConsolidatedMember1545000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration_NonConsolidatedMember－JPY
Loss on sales of noncurrent assets elCurrentYTDDuration_NonConsolidatedMember14000JPY
Extraordinary lossPrior1YTDDuration_NonConsolidatedMember－JPY
Extraordinary lossCurrentYTDDuration_NonConsolidatedMember14000JPY
Income before income taxesPrior1YTDDuration_NonConsolidatedMember-1023801000JPY
Income before income taxesCurrentYTDDuration_NonConsolidatedMember-914707000JPY
Income taxes currentPrior1YTDDuration_NonConsolidatedMember3757000JPY
Income taxes currentCurrentYTDDuration_NonConsolidatedMember3757000JPY
Income taxesPrior1YTDDuration_NonConsolidatedMember3757000JPY
Income taxesCurrentYTDDuration_NonConsolidatedMember3757000JPY
Profit lossPrior1YTDDuration_NonConsolidatedMember-1027559000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identitynon_consolidated 2022-12-31pass
balance sheet identitynon_consolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-09-30pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-09-30pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-09-30pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-09-30pass